about
TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expressionIL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNγOncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.French Intensive Care Society, International congress - Réanimation 2016Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Double-intensive therapy in high-risk multiple myeloma.A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 studyNOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.[Hematologic manifestations related to hepatitis A virus. 3 cases]Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupComputed microtomography of bone specimens for rapid analysis of bone changes associated with malignancy.Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients.Comprehensive mutational profiling of core binding factor acute myeloid leukemia.International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Mutations in TP53 are exclusively associated with del(17p) in multiple myelomaPhase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.Site- and allele-specific polycomb dysregulation in T-cell leukaemiaSemaphorin 3F and neuropilin-2 control the migration of human T-cell precursorsHigh levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTRFactors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance.Targeting IRAK1 in T-cell acute lymphoblastic leukemiaProspective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia studyInhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaCytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLAcute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.
P50
Q24315660-95891D41-EF0B-4016-92F5-3A175AD7D6E1Q24317213-6832C5D6-0356-4AC7-A566-FAB3D5B7C89BQ27852997-6F3625FC-A225-46E1-BF46-85BA77EFAB52Q28550357-954AEADC-0DD5-4733-B8FB-8E0DC2DEA92EQ30835785-B3621848-D4BD-4290-95F2-0EC977AA2F21Q33352090-B7F40D35-67D6-48F2-9CCC-2C45C43EF7D6Q33361012-54F655FD-156F-4323-905F-91D44F3DA6C3Q33392436-F3B3A43A-2638-4FB9-8FB9-7669DFB58A80Q33395926-497D44CE-B374-453C-A082-703D7EE0F607Q33499702-816CD4D4-6FF5-4651-B4F7-D5A46A9CA001Q33558123-BB6F4DAA-D1F2-421B-BB40-FD8671FA7E4EQ33618079-BBE16A91-28A4-4326-90D6-549000AF6CC1Q33632278-F50C5639-FF3C-476B-9FAC-66773E8869E0Q33734571-0C268666-DC99-43B6-8E11-AE36CCD76540Q33745000-0586CD06-291F-4B66-AC9A-9B31EBB02BBCQ33758306-63C7D911-8F08-4512-90F8-895BBB6AE319Q33822004-8CFB215B-51E4-4D99-9600-0A75876C5D60Q34088767-D4360A31-2798-44D1-91A3-7C375964DB6EQ34106837-17373C54-8FC1-4943-8F70-EE51F1AD0C0DQ34255215-77895122-DAC9-44DA-A32D-63B68658A3A2Q34293391-71A51166-4316-4CCD-9223-089A512DEE4DQ34584443-905415FE-5C75-410E-BD40-D03FA2E824A4Q34714888-68E775CD-D77F-4AC7-9E6A-89355B25DC46Q35050495-3D5C3BA8-A39E-47CF-BAAD-DDBA9C2FC49EQ35214194-11BE01C9-2DC3-4693-A220-C81FC32EE77FQ35596914-59D11216-2285-4020-ADC7-DB5EC88B9BC2Q35602915-82250601-9881-4E35-B55B-F832605669A4Q35669870-39B497F3-FB63-4CAC-A769-144C09638B97Q35767384-9119AA0D-338A-418A-82FA-C7B77F95A383Q35848083-151A0E5D-36AE-4758-ABF9-BFE85748289CQ36022586-57EA664B-099C-4F44-8D21-01992F502EA1Q36326296-BE02CF6E-07E6-4975-BF11-ED52AA1608EDQ36750458-469552AB-A57C-4084-B8DD-28E27F9E1B3BQ37144910-823E6F52-A8F9-436A-80DF-74CDF6ADACF7Q37237899-049D053C-79D7-48C5-A917-7853AAC85428Q37311260-EDF8F994-7CE0-4C66-9383-0721FA1090A9Q37325019-6D4244FD-965F-407F-A341-64B305EEA013Q37349113-2A2A944A-3DBD-4B17-B838-1CFB574194EAQ37376595-7EC1B9BA-D243-4CF9-B3A1-76B443DDD634Q37575938-AA512CCD-96C1-4717-ACC8-3BA787F43492
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Norbert Ifrah
@ast
Norbert Ifrah
@en
Norbert Ifrah
@es
Norbert Ifrah
@nl
type
label
Norbert Ifrah
@ast
Norbert Ifrah
@en
Norbert Ifrah
@es
Norbert Ifrah
@nl
prefLabel
Norbert Ifrah
@ast
Norbert Ifrah
@en
Norbert Ifrah
@es
Norbert Ifrah
@nl
P106
P21
P31
P496
0000-0003-3063-850X